Laquinimod

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Laquinimod

Postby Marknamealreadytaken » Fri May 13, 2005 8:58 pm

anyone discuss this with their Doc. does it look like this will be on the market soon??
User avatar
Marknamealreadytaken
Newbie
 
Posts: 5
Joined: Fri May 13, 2005 2:00 pm

Advertisement

Postby dignan » Sat May 14, 2005 5:59 am

Laquinimod is supposedly in the early stages of a Phase III trial right now, although the article below is the latest thing I can find about it's status and it says they are still conducting additional Phase II studies. All this to say that it is probably at least 3 years away from being available to anybody other than trial participants...or are you considering participating in a trial?


Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology

BUSINESS WIRE - March 22, 2005 - Teva Pharmaceutical Industries and Active Biotech announced today that the final report of the Phase II study of laquinimod, which was successfully concluded in September 2003, has been published today in NEUROLOGY:

"Treatment with laquinimod reduces development of active MRI lesions in relapsing MS" by C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle and T. Nederman". Neurology 2005; vol.64, No.6 p. 987.

Laquinimod is a novel immunomodulatory substance developed by Active Biotech. It has the potential to be the first orally-available disease modifying treatment for multiple sclerosis (MS).

In June 2004, Teva and Active Biotech signed an agreement for the future global development and commercialization of laquinimod.

The objective of the concluded Phase II study was to evaluate, in relapsing MS patients, the efficacy of 2 doses of laquinimod compared to placebo, based on its ability to suppress the development of active MRI lesions, as well as its safety and tolerability. It was concluded that daily treatment with laquinimod at a dose of 0.3 mg, reduced the mean cumulative number of active lesions by 44% compared to placebo (p less than 0.05) Its safety profile was very favorable; there were no clinical signs of undesired inflammatory manifestations.

Currently, additional Phase II studies are ongoing, aimed at evaluating the benefit of higher doses of laquinimod.

http://home.businesswire.com/portal/sit ... ewsLang=en
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 2:00 pm

trial

Postby Marknamealreadytaken » Sat May 14, 2005 12:53 pm

I would consider it
User avatar
Marknamealreadytaken
Newbie
 
Posts: 5
Joined: Fri May 13, 2005 2:00 pm

Postby amelia » Tue May 31, 2005 6:41 am

Is this 4AP? 4 aminopyridine was mentioned in the article. It is a compound mixed up by pharmacist now. My hsuband has been on it for years. His DR said at the last visit that it was going to come out soon in a time released pill. Is this what she was talking about?
User avatar
amelia
Family Elder
 
Posts: 309
Joined: Wed Feb 09, 2005 3:00 pm
Location: grenada, ms


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service